Close Menu

Gilead Sciences

Trodelvy's clinical development in China, led by Everest Medicines, follows the agent's US accelerated approval in April for triple-negative breast cancer. 

The collaboration will focus on the discovery, development, and commercialization of targeted immune evasion therapies for patients with cancer.

The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.

The agreement is part of Biocartis' long term plans to expand its presence in the oncology field by building a menu of tests for immunotherapies.